Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Synthesis and characterization of GLP-1RAs@NPs-WYRGRL To enhance the local concentration, stability, and retention time of GLP-1RAs in the joint area, GLP-1RAs were encapsulated into silk fibroin nanoparticles (GLP-1RAs@NPs) and the surface of GLP-1RAs@NPs was further modified with the WYRGRL peptide, thereby developing GLP-1RAs@NPs-WYRGRL for the treatment of RA (Fig
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)
As we have seen with GLP-1 drugs, once a therapy demonstrates both biological efficacy and real-world impact, adoption can accelerate very quickly. Whether through stem cell activation, immune modulation, reformulated legacy drugs, or regenerative medicine, the next generation of hair loss therapies is no longer chasing incremental improvement
An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics
Step 2: Calculate and Administer Loading Phase Subcutaneous Injections Melanotan-1 requires a loading phase to saturate melanocyte MC1R receptors before maintenance dosing achieves visible pigmentation
